Q-omics provides the consensus-scored NDRG1 profile across patient tissues and cancer cell-line models. NDRG1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NDRG1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, NDRG1 protein abundance shows 37,171 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight BRCA, KIRC, and HNSC as cancer lineages where NDRG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDRG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDRG1 survival associations across molecular data types. NDRG1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDRG1 RNA expression–survival associations across cancer types. High NDRG1 expression shows unfavorable associations in BRCA, ACC, LIHC, KIRP and UCS, but favorable associations in KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for NDRG1 RNA expression.
This table summarizes NDRG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 13. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDRG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDRG1 shows lower tumor expression in THCA and COAD and higher tumor expression in KIRC, HNSC, LIHC and LUSC. The KIRC box plot shows higher NDRG1 RNA expression in tumor versus normal tissue (log2 FC = +2.147, t-test p < 0.001).
This table shows molecular features associated with NDRG1 in patient tissues and cancer cell lines. In patient samples, NDRG1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, NDRG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
